Jad Chahoud Shared SWOG S1512 Trial Results
Jad Chahoud, Genitourinary Medical Oncologist at Moffitt Cancer Center, shared a recent article by Kari L. Kendra and colleagues on X:
“SWOG S1512 (phase 2): In unresectable desmoplastic melanoma, pembrolizumab showed 89% ORR, 37% CR, 3-yr OS 96%. Supports PD-1 monotherapy as standard for this rare melanoma subtype ”
Title: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial
Authors: Kari L. Kendra, Shay L. Bellasea, Zeynep Eroglu, Siwen Hu-Lieskovan, Katie M. Campbell, William E. Carson III, David A. Wada, Jose A. Plaza, Jeffrey A. Sosman, Gino K. In, Alexandra Ikeguchi, John Hyngstrom, Andrew S. Brohl, I. Khushalani Nikhil, Joseph Markowitz, George Negrea, Samer Kasbari, Gary C. Doolittle, Umang Swami, Toni Roberts, Boban N. Mathew, Egmidio Medina, Ignacio Baselga-Carretero, Cynthia R. Gonzalez, Ivan Perez Garcilazo, Agustin Vega-Crespo, Jia Ming Chen, Nataly Naser Al-Deen, Sapna P. Patel, Elad Sharon, James Moon, Michael C. Wu, Antoni Ribas
More posts featuring Jad Chahoud on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023